摘要
目的:探讨阿帕替尼治疗老年性胃癌的临床疗效及不良反应,以期为老年性胃癌的临床诊治提供参考依据。方法:选择某院收治的32例老年性胃癌患者,随机分为观察组和对照组,每组各16例,对照组给予阿帕替尼模拟片治疗,观察组给予阿帕替尼治疗。比较2组患者的临床疗效,并观察阿帕替尼药物治疗的不良反应发生率。结果:观察组患者部分缓解(PR)、病情稳定(SD)、病情进展(PD)及疾病控制率(DCR)均优于对照组,差异有统计学意义(P<0.05);阿帕替尼的不良反应主要有高血压、蛋白尿、骨髓抑制,其中高血压的发生率为50.0%,骨髓抑制的发生率为43.8%,蛋白尿的发生率为37.5%。结论:阿帕替尼可有效控制老年性胃癌病情,不良反应可耐受,值得临床推广应用。
Objective :To analyze the clinical efficacy and adverse reactions of apatinib in treatment of senile gastric canceRso as to provide reference foRclinical diagnosis and treatment. Methods :32 patients with senile gastric canceRadmitted to hospital were randomly divided into two groups,each with 16 cases.The 16 patients in the control group were treated with simulated tablets of apatinib,while those in the observation group were treated with apatinib.The clinical efficacy of the two groups of patients was compared and the incidence of adverse reactions treated with apatinib was observed. Results :The PR,SD,PD and DCRof the observation group were betteRthan those of the control group,the difference being statistically significant( P <0.05).The adverse reactions of apatinib mainly include hypertension, proteinuria and myelosuppression (50.0%, 43.8%, 37.5% respectively). Conclusion :Apatinib can effectively control the condition of senile gastric cancer, and the adverse reactions can be tolerated. It is worthy of clinical application.
作者
李露
钟春生
LI Lu;ZHONG Chun-sheng(Department of Oncology,Bengbu No.3 People'sHospital,Anhui 233000,China)
出处
《淮海医药》
CAS
2019年第3期244-246,共3页
Journal of Huaihai Medicine